This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEUVEN, Belgium, April 14, 2014 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, notes the recent media speculation regarding its strategic review.
As announced on 24 February 2014, ThromboGenics is currently exploring strategic options for the Company, to allow it to realize the significant commercial potential of JETREA® in the US, and to fully exploit the Company's proven product development capabilities.
The strategic review is at a preliminary stage. The Company does not intend to comment further on market speculation unless and until it otherwise deems further disclosure is appropriate or required.
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA
® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.
In Europe, JETREA
® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA
® outside the United States. ThromboGenics and Alcon intend to share the costs equally of developing JETREA
® for a number of new vitreoretinal indications.
ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of oncology indications.